P-319 Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA

Evangelos Terpos; Ioannis Ntanasis‐Stathopoulos; Maria Gavriatopoulou; Eirini Katodritou; Evdoxia Hatjiharissi; Panagiotis Malandrakis; Evgenia Verrou; Alexandros Leonidakis; Magdalini Migkou; Sosana Delimpasi; Argiris Symeonidis; Efstathios Kastritis; Meletios A Dimopoulos

doi:10.1016/s2152-2650(23)01937-7

Article2024

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study <scp>DARIA</scp>

Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Panagiotis Malandrakis, Evgenia Verrou, Stavros Golfinopoulos, Magdalini Migkou, Kyriaki Manousou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos

Article2021

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Alexandros Leonidakis, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos

Article2020

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Alexandros Leonidakis, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos

Article2023

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Kyriaki Manousou, Stavros Gkolfinopoulos, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos

Article2024

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

Sosana Delimpasi, Meletios A Dimopoulos, Jan Štraub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesús G. Berdeja, Petr Pavlíček, Jeffrey Matous, Paweł Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

P-319 Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA

Discussion(0)

Related publications

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study <scp>DARIA</scp>

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma